ImetelChat

Okay, I may not have read this closely enough but if we do some basic math from this study’s conclusions and extrapolate to the 100,000 MDS patients with LR MDS from the HC Wainwright presentation. I think we can say that half of those patients have a transfusion burden of >= 8/16 weeks. Then 50,000...

Well if they could find a way to remove the telomeres from the cancerous cells and add to the healthy ones maybe we could live longer but wiser is a crapshoot. :D To your theme of asking the analysts to step up, you might want to start formulating your hard questions similar to the annual meeting wh...

I expect you are on target as usual. I believe this could be “back to the future” in spades. There are lots of treatments, drugs and homeopathic / vitamin remedies that will kill cells and/or rev up the immune system. However, what is needed for tumors is more of a rifle shot vs a shotgun delivery o...

Interesting post as always biopearl123! Given the title “Oligonucleotide-Functionalized Gold Nanoparticles for Synchronous Telomerase Inhibition, Radiosensitization, and Delivery of Theranostic Radionuclides” gives us neophytes pause as usual. But after having sloshed around in this article and rela...

Good information biopearl123, I think that is exactly why Geron is using the DM terminology with the idea that Imetelstat is clearly differentiated from competition available or in development! I think there is more here than meets the eye. Dr. Mascarenhas actually let some of that out of the bag so...

Good questions Zhears. I am merely a retired investor so can’t answer the questions although I do have two cents worth of opinions. Other members here should share their thoughts as well. I do think lack of activity can be meaningful and in the case of Geron options, it is a little strange to see so...

Hi Zhears, agreed as it seems we never get all our pressing questions answered. It is always prudent to be a contrarian especially with a pre-commercial biotech. The Form 10Q report submitted to the SEC, contains COVID-19 info ad nauseum so they have focused heavily on the associated risks. It is pr...

Agreed! This was a great CC by Dr. John Scarlett and his executive team, maybe a watershed point. And to your comments biopearl123, it was polished, positive, optimistic, answered some key questions and covered several new subjects. And to your point rccola335, stay tuned in reference to a partner, ...

Thanks ashah for the info on the crossover. It was right there in front of me but I stopped reading just before and concluded incorrectly. The other thing from the CC yesterday was the MF study is not double blinded per Dr. Rizo, it is only randomized. Of course that is also stated in the CT info bu...

Thanks biopearl123 for keeping this on track and to be fair, the MF P3 study has a comparator of best available therapy (BAT) which is investigator-selected non-JAK-inhibitor treatment and not a placebo. However, for the most part it seems to me it is a blank load for the R/R patients, just not tech...

Okay, so I may be standing out in the wilderness mostly alone on this but the gold standard could be interpreted more than one way, for example to mean the majority of phase 3 trials using a placebo which could benefit study quality and/or not be significantly detrimental to the patients is one way ...

Thanks all for the nice comments. And I appreciate the follow-up kmall! So I did find biopearl123’s post (Reality check – on July 20, 2018). Those are significant numbers and I assume the FDA or any health regulatory or medical entity would not overlook such critical potential and add their support ...

Thank you biopearl123 for posting the link to this MDS article. I found it covering the scope and depth of the disease in an enlightening way. For me, it provided perspective on the treatment paradigms for both low and high risk MDS and attempts to tie the various MDS therapeutic options together in...

https://www.sskrplaw.com/the-double-blind-placebo-controlled-trial-the-fool-s-gold-standa.html Someone posted this on the YMB a few days ago. When went back to see who posted it, it apparently had been erased. This document was on a law firms website publications tab. I found it very interesting and...

Listening to the CRIS earnings call highlights several differences between CRIS / Geron management and the drugs and their targets. Given the current state of their studies with Geron considerably ahead in my opinion, comparing DM statements might be a fool’s game. CRIS CEO Jim Dentzer is very marke...

ashah, thanks for your thoughts, you make a good point in that the work in the trenches, SOP, blocking and tackling etc. must come first, the ante so to speak. However, I do think getting the CTs fully enrolled is both critical and strategic, not icing or cheerleading. If the CTs are filling nicely,...

Lastly, here are a couple things I’ve recently picked up that I think are of interest and probably informative for some of us. First link is an article is by Dr. John Mascarenhas including info on patients that are triple negative: Understanding Genetic Mutations in Primary Myelofibrosis When should...

Part VI: Clinical Trials (MF / MDS): I think we all have a little time here to do some due diligence regarding the various drugs in CTs that may help patients with these diseases and why, help us better understand the enormity of the competitive landscape and learn more about the challenges for a p...

Part V: Complete Blood Count (CBC) NOW, I’m going to chime in here!! If you get annual checkups and have never gotten a complete blood count (CBC), please ask for one on your next checkup or just your next doctor’s appointment and take the time to study the results yourself. Also, ask them to inclu...

Part IV: Who needs a blood transfusion and what are the risks? You may need a blood transfusion if you have anemia, sickle cell disease, a bleeding disorder such as hemophilia, cancer or severe injury. For people in critical condition, blood transfusions can be lifesaving. Four types of blood produ...